Abstract
Several cephalosporins are in clinical development as broad-spectrum agents with potent activity against multi-resistant staphylococci as well as the Gram-positive and Gram-negative bacteria normally susceptible to advanced generation cephalsoporins. These agents represent a novel activity for the class and challenge a dogma that beta-lactams do not have clinically useful activity against multi-resistant staphylococci. The most advanced of these agents, ceftobiprole, is approaching registration and, if approved, will present physicians with a new paradigm in treatment of serious infections by multi-resistant organisms.
MeSH terms
-
Animals
-
Anti-Bacterial Agents* / chemistry
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Bacterial Infections / drug therapy*
-
Bacterial Infections / microbiology
-
Cephalosporins* / chemistry
-
Cephalosporins* / pharmacology
-
Cephalosporins* / therapeutic use
-
Clinical Trials as Topic
-
Drug Design*
-
Drug Industry
-
Drug Resistance, Bacterial
-
Gram-Negative Bacteria / drug effects
-
Gram-Negative Bacteria / isolation & purification
-
Gram-Positive Bacteria / drug effects
-
Gram-Positive Bacteria / isolation & purification
-
Humans
-
Microbial Sensitivity Tests
-
Molecular Structure
Substances
-
Anti-Bacterial Agents
-
Cephalosporins